BeOne Medicines' first quarter revenue jumped 35% to $1.51B on strong Brukinsa sales, leading to a raised FY26 forecast.

BeOne Medicines reported first quarter 2026 revenue of $1.51 billion, up 35% year-over-year, and non-GAAP diluted EPS of $3.24 per ADS. The results significantly surpassed analyst expectations, driven by strong global sales of its foundational oncology drug, BRUKINSA. The company also raised its full-year 2026 financial guidance for revenue and operating income.

Key Highlights

• The company's key drug, BRUKINSA, generated global sales of $1.1 billion, an increase of 38% year-over-year, exceeding analyst estimates.
• BeOne raised its full-year 2026 revenue guidance to a range of $6.3 billion to $6.5 billion, up from the previous range of $6.2 billion to $6.4 billion.
• The company demonstrated significant operating leverage, with GAAP net income reaching $227 million, a substantial increase from just $1.3 million in the same quarter last year.